Skip to content

Study · Animal study (in vivo) · mouse · 2007

16 results

Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells.

Sherry NA, Chen W, Kushner JA, Glandt M, Tang Q, Tsai S, Santamaria P, Bluestone JA, Brillantes AM, Herold KC

Endocrinology2 Aug 2007Cited by 137 (Europe PMC)

PMID17673522 (opens in a new tab)DOI10.1210/en.2007-0358 (opens in a new tab)PepBankPUB-17673522
Source linkPubMedAsk about this study
Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic NOD mice, adding exendin‑4 to anti-CD3 increased remission versus anti-CD3 alone.

    In plain wordsIn mice, adding exendin‑4 increased diabetes remission compared with anti-CD3 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseRemission versus anti-CD3 alone
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Comparator
    Anti-CD3 mAb alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Remission
    44%
    combination
    Remission
    37%
    anti-CD3 alone

    Source sentences

    Summary
    Diabetic NOD mice treated with anti-CD3 mAb and exendin-4 had a higher rate of remission (44%) than mice treated with anti-CD3 mAb alone (37%) or exendin-4 (0%) or insulin or IgG alone (0%) (P < 0.01).
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic NOD mice, exendin‑4 alone produced no remission.

    In plain wordsIn mice, exendin‑4 alone produced no diabetes remission.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableExendin-4 monotherapy remission
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Remission
    0%
    exendin-4 alone

    Source sentences

    Summary
    Diabetic NOD mice treated with anti-CD3 mAb and exendin-4 had a higher rate of remission (44%) than mice treated with anti-CD3 mAb alone (37%) or exendin-4 (0%) or insulin or IgG alone (0%) (P < 0.01).
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In NOD mice with lower diagnostic glucose, exendin‑4 enhanced diabetes reversal after anti-CD3 treatment.

    In plain wordsIn mice with lower starting glucose, adding exendin‑4 improved diabetes reversal compared with anti-CD3 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseRemission at lower diagnostic glucose
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Comparator
    Anti-CD3 mAb alone
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect of exendin-4 on reversal of diabetes after anti-CD3 mAb was greatest in mice with a glucose level of less than 350 mg/dl at diagnosis (63 vs. 39%, P < 0.05).
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In NOD mice, exendin‑4 did not affect beta-cell area.

    In plain wordsIn mice, exendin‑4 did not change the area of insulin-producing cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBeta-cell area
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 did not affect beta-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  5. 05AnimalAnimal study (in vivo)Mechanism

    In NOD mice, exendin‑4 did not affect beta-cell replication.

    In plain wordsIn mice, exendin‑4 did not change replication of insulin-producing cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBeta-cell replication
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 did not affect beta-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  6. 06AnimalAnimal study (in vivo)Mechanism

    In NOD mice, exendin‑4 did not affect beta-cell apoptosis.

    In plain wordsIn mice, exendin‑4 did not change death of insulin-producing cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeBeta-cell apoptosis
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 did not affect beta-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  7. 07AnimalAnimal study (in vivo)Mechanism

    In NOD mice, exendin‑4 did not reduce diabetogenic T-cell frequency.

    In plain wordsIn mice, exendin‑4 did not reduce the frequency of diabetes-promoting immune cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeDiabetogenic T cells
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 did not affect beta-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  8. 08AnimalAnimal study (in vivo)Mechanism

    In NOD mice, exendin‑4 did not reduce regulatory T-cell frequency.

    In plain wordsIn mice, exendin‑4 did not reduce regulatory immune cell frequency.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeRegulatory T cells
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 did not affect beta-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  9. 09AnimalAnimal study (in vivo)Mechanism

    In NOD mice, exendin‑4 did not modulate islet-cell antigenicity.

    In plain wordsIn mice, exendin‑4 did not change the immune recognition properties of islet cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeIslet antigenicity
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Immune response · Immune and inflammation
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Exendin-4 did not affect beta-cell area, replication, or apoptosis or reduce the frequency of diabetogenic or regulatory T cells or modulate the antigenicity of islet cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  10. 10AnimalAnimal study (in vivo)Mechanism

    In the NOD mouse study, exendin‑4 increased beta-cell insulin content.

    In plain wordsIn mice, exendin‑4 increased insulin content in insulin-producing cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeta-cell insulin content
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Glucose tolerance and insulin responses improved in mice treated with combination therapy, and exendin-4 increased insulin content and insulin release from beta-cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.
  11. 11AnimalAnimal study (in vivo)Mechanism

    In the NOD mouse study, exendin‑4 increased beta-cell insulin release.

    In plain wordsIn mice, exendin‑4 increased insulin release from insulin-producing cells.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseBeta-cell insulin release
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Glucose tolerance and insulin responses improved in mice treated with combination therapy, and exendin-4 increased insulin content and insulin release from beta-cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.

Studies that did not test the peptide alone5

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 12AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome

    In diabetic NOD mice, anti-CD3 plus exendin‑4 produced more remission than exendin‑4 alone.

    In plain wordsIn mice, anti-CD3 plus exendin‑4 produced more diabetes remission than exendin‑4 alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCombination remission versus exendin-4 alone
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Comparator
    Exendin-4 alone
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Diabetic NOD mice treated with anti-CD3 mAb and exendin-4 had a higher rate of remission (44%) than mice treated with anti-CD3 mAb alone (37%) or exendin-4 (0%) or insulin or IgG alone (0%) (P < 0.01).
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 13AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome

    In diabetic NOD mice, anti-CD3 plus exendin‑4 produced more remission than insulin alone.

    In plain wordsIn mice, anti-CD3 plus exendin‑4 produced more diabetes remission than insulin alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCombination remission versus insulin
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Comparator
    Insulin alone
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Diabetic NOD mice treated with anti-CD3 mAb and exendin-4 had a higher rate of remission (44%) than mice treated with anti-CD3 mAb alone (37%) or exendin-4 (0%) or insulin or IgG alone (0%) (P < 0.01).
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 14AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome

    In diabetic NOD mice, anti-CD3 plus exendin‑4 produced more remission than IgG alone.

    In plain wordsIn mice, anti-CD3 plus exendin‑4 produced more diabetes remission than IgG alone.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCombination remission versus IgG
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Comparator
    IgG alone
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Diabetic NOD mice treated with anti-CD3 mAb and exendin-4 had a higher rate of remission (44%) than mice treated with anti-CD3 mAb alone (37%) or exendin-4 (0%) or insulin or IgG alone (0%) (P < 0.01).
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 15AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome

    In NOD mice, glucose tolerance improved with anti-CD3 plus exendin‑4.

    In plain wordsIn mice, glucose tolerance improved during anti-CD3 plus exendin‑4 treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCombination glucose tolerance
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Glucose tolerance and insulin responses improved in mice treated with combination therapy, and exendin-4 increased insulin content and insulin release from beta-cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 16AnimalNot a test of Exenatide (exendin-4) aloneAnimal study (in vivo)Efficacy outcome

    In NOD mice, insulin responses improved with anti-CD3 plus exendin‑4.

    In plain wordsIn mice, insulin responses improved during anti-CD3 plus exendin‑4 treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseCombination insulin responses
    Study

    mousen: not reported in source

    Diabetic NOD mice
    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    Glucose tolerance and insulin responses improved in mice treated with combination therapy, and exendin-4 increased insulin content and insulin release from beta-cells.
    1 context sentence
    Summary · context
    We tested whether exendin-4, a glucagon-like peptide-1 receptor agonist, would enhance remission of T1DM in NOD mice treated with anti-CD3 monoclonal antibody (mAb) and studied the effects of exendin-4 treatment on cellular and metabolic responses of beta-cells.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.